Short-acting β-blocker administration in patients with septic shock [2]

JAMA

Volumn 311, Issue 7, 2014, Pages 736-

  Sanfilippo, Filippo ^a   Santonocito, Cristina ^a   Maybauer, Marc Oliver ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESMOLOL; LACTIC ACID; LEVOSIMENDAN; NORADRENALIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROPANOLAMINE DERIVATIVE;

CARDIOVASCULAR PARAMETERS; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; FLUID THERAPY; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART STROKE VOLUME; HUMAN; LACTATE BLOOD LEVEL; LEFT VENTRICULAR STROKE WORK INDEX; LETTER; MORTALITY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SYSTEMIC VASCULAR RESISTANCE; FEMALE; MALE; NOTE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; FEMALE; HEART RATE; HUMANS; MALE; PROPANOLAMINES; SHOCK, SEPTIC;

EID: 84894202145     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.315     Document Type: Letter

References (3)

1. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683-1691.
2. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31(5):638-644. (Pubitemid 40684980)
3. Orion Corporation. Orion updates information about Abbott's progress with Simdax. http://www.orion.fi/en/News-and-media/Stock-exchange-releases/Archive/ 4/44/. Accessed December 13, 2013.